Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBC-11004
- Development stage
- Preclinical
- Lead developer
- Gradiant Bioconvergence
- Modality
- Small Molecules
01
Overview
GBC-11004 is a small molecule drug developed by Gradiant Bioconvergence, currently in preclinical development for the treatment of non-small cell lung cancer (NSCLC). It is being investigated as a novel therapeutic target to overcome resistance to osimertinib in NSCLC treatment. The drug is also considered for potential use in other neoplasms and respiratory diseases[1][2][3].
- Other names
- GBC-11004 InhibitorGBC11004 InhibitorGBC 11004 Inhibitor
Beyond the preview
Go deeper on GBC-11004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBC-11004.